ALKS Q4 2022 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$305M-6.1% YoY

Gross Profit

$251M82.3% margin

Operating Income

-$21M-6.8% margin

Net Income

-$28M-9.3% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

+20.7%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

-$9M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$920M

Stockholders' Equity

$1.0B

Cash & Equivalents

$292M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$305M	$324M	-6.1%
Gross Profit	$251M	$271M	-7.4%
Operating Income	-$21M	$2M	-963.7%
Net Income	-$28M	$873,000	-3336.4%

Revenue Segments

Product

$216M50%

Vivitrol

$102M24%

Aristada And Aristada Initio

$79M18%

L Y B A L V I

$35M8%